Autopsy report · NCT01859637

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Cause of deathRegulatory or ethics Automatic label, confidence 0.9, unverified. How labels are made.

“Additional pharmacovigilance activity was considered as fulfilled by the EMA.”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 10 months after it had already started.
Ran for about 4 years 2 months before it stopped.
6 participants enrolled.
Results were posted on the registry 6 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: Sandoz
Sponsor type: Industry
Conditions: Severe Chronic Neutropenia
Interventions: Filgrastim
Participants: 6
Sites: 2
Countries: Germany, Sweden

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.